GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Metagenomi Inc.
Metagenomi, a gene editing company, is a bet on the future of medicine. Its post-IPO price reflects the enormous potential of its technology platform, but also the very long and risky path from the lab to a commercial drug.
Share prices of companies in the market segment - Dna
Metagenomi is a gene editing company that uses a vast database of microbial genomes to discover and develop new editing systems (CRISPR analogs) for gene therapy. We've classified it in the "DNA" segment. The chart below shows the overall dynamics in this cutting-edge sector, where the race is on to create the best "molecular scissors."
Broad Market Index - GURU.Markets
Metagenomi is a biotech company developing a new generation of gene-editing tools for therapeutic applications. Its cutting-edge science makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Metagenomi compares to it.
Change in the price of a company, segment, and market as a whole per day
MGX - Daily change in the company's share price Metagenomi Inc.
Metagenomi, Inc.'s daily share price fluctuations reflect the high volatility inherent in gene editing companies. This metric measures the company's sensitivity to scientific breakthroughs and partnership news, serving as a risk assessment tool.
Daily change in the price of a set of shares in a market segment - Dna
Metagenomi, Inc.'s daily share price fluctuations reflect the high volatility inherent in gene editing companies. This metric measures the company's sensitivity to scientific breakthroughs and partnership news, serving as a risk assessment tool.
Daily change in the price of a broad market stock, index - GURU.Markets
Metagenomi is a biotech company developing a new generation of gene editing tools. It's at the cutting edge of science, where every successful experiment has the potential to revolutionize medicine. Its stock price fluctuates, reflecting the high hopes and risks of genetic engineering, adding a futuristic and volatile rhythm to the overall market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Metagenomi Inc.
For Metagenomi, Inc., year-over-year performance is a reflection of its extensive gene-editing toolkit. Its 12-month market cap depends on progress in its preclinical programs and, more importantly, on partnerships with major pharmaceutical companies seeking to use its unique enzymes to create new gene therapies.
Annual dynamics of market capitalization of the market segment - Dna
Metagenomi, a recent IPO, is one of the leading companies in the field of next-generation gene editing. Its extensive enzyme library is its key advantage. The chart shows how the market views its technological potential compared to other CRISPR pioneers, such as CRISPR Therapeutics.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Metagenomi, a pioneer in genome editing, is a bet on the technology of the future. Its stock price since its IPO has been completely unrelated to the economy. Its price chart reflects the hopes, risks, and scientific breakthroughs in one of the most cutting-edge fields of medicine. It's a long-term bet on technology.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Metagenomi Inc.
Metagenomi is a company at the forefront of gene editing. Being an early-stage company, its monthly valuation is based on the potential of its technology platform. News of scientific breakthroughs, partnerships with major pharmaceutical companies, and progress in preclinical research are the main drivers.
Monthly dynamics of market capitalization of the market segment - Dna
Metagenomi is a biotechnology company developing a new generation of genome editing systems based on natural methods. Its goal is to create tools more precise and versatile than CRISPR/Cas9. The genetic engineering sector chart reflects the overall interest in this revolutionary field and allows us to assess the potential and risks of Metagenomi's cutting-edge platform.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Metagenomi is a gene editing company. This is one of the most advanced and risky areas of biotechnology. The company's shares move not in response to the market, but in anticipation of scientific breakthroughs. Any news about the technology can cause sharp fluctuations, completely ignoring overall economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Metagenomi Inc.
Metagenomi, Inc., a gene editing company, whose weekly stock price reflects the cutting edge of biotechnology. News about the development of new editing systems, partnerships, and scientific breakthroughs are driving extremely volatile short-term trends.
Weekly dynamics of market capitalization of the market segment - Dna
Metagenomi is a pioneer in gene editing, developing a new generation of gene therapy tools. The chart will show how investors view its breakthrough yet risky scientific potential compared to the overall biotech sector, reflecting their belief in the future of medicine.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Metagenomi is a pioneer in gene editing. Its stock is a bet on future technologies. The chart shows that MGX's performance is largely uncorrelated with the market, driven by news of scientific breakthroughs.
Market capitalization of the company, segment and market as a whole
MGX - Market capitalization of the company Metagenomi Inc.
Metagenomi's stock price is a financial frontier in the world of genetic engineering. The market cap of this company, which uses metagenomics to discover new gene editing systems, reflects faith in its technology platform. Its momentum is a bet that its tools will outperform existing technologies like CRISPR.
MGX - Share of the company's market capitalization Metagenomi Inc. within the market segment - Dna
Metagenomi's stake in the DNA technology sector is a bet on the next generation of gene editing. The company is developing a comprehensive suite of genetic engineering tools that surpass standard CRISPR. Its position reflects the enormous potential of its platform for creating new treatments.
Market capitalization of the market segment - Dna
Metagenomi is one of the leading companies in the field of next-generation genome editing. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics are a barometer of investor confidence in the potential of this revolutionary technology to treat previously incurable diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Metagenomi is a genome editing company developing a large library of enzymes for the creation of new gene therapies. Its market capitalization is a bet on its technology platform. The chart below shows the economic weight of biotech tool companies.
Book value capitalization of the company, segment and market as a whole
MGX - Book value capitalization of the company Metagenomi Inc.
Metagenomi, a genome editing company, derives its book value from its capital and laboratory equipment. The chart below shows the financial and scientific resources devoted to creating a new generation of genetic engineering tools. This is a story of capital transforming into cutting-edge science.
MGX - Share of the company's book capitalization Metagenomi Inc. within the market segment - Dna
Metagenomi is a gene editing company. Its value lies in its vast enzyme library and scientific platform. Its share of tangible assets will reflect its focus on R&D, where its key assets are its cutting-edge laboratories.
Market segment balance sheet capitalization - Dna
Metagenomi is a gene editing company. Its assets are not factories, but cutting-edge laboratories where new "genetic scissors" are being established and developed. This is capital-intensive R&D. The chart will show how "lightweight" the entire nascent gene therapy sector is compared to traditional pharmaceutical giants.
Book value of all companies included in the broad market index - GURU.Markets
Metagenomi's balance sheet is capital invested in the creation and development of a comprehensive database of gene editing tools found in nature. The company's assets comprise its unique scientific "library," which could serve as the basis for the creation of next-generation gene therapies.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Metagenomi Inc.
Metagenomi is a biotech company developing a new generation of gene editing systems. Its value lies in its vast enzyme library and technology platform. The chart shows how investors view it as a potential leader in the next wave of genetic engineering, evaluating its science rather than its assets.
Market to book capitalization ratio in a market segment - Dna
Metagenomi is a gene editing company developing new tools for gene therapy. Its valuation is based almost entirely on the potential of its scientific platform. The chart shows the significant premium the market is paying for this cutting-edge technology.
Market to book capitalization ratio for the market as a whole
Metagenomi is a company developing next-generation gene editing technologies. The chart shows how the market values one player in the next wave of the biotech revolution. Its high market capitalization reflects a bet that its genome editing tools will be more precise and effective than existing ones.
Debts of the company, segment and market as a whole
MGX - Company debts Metagenomi Inc.
Metagenomi is a gene editing company developing a new generation of tools for potential treatment of genetic diseases. This chart shows how the company is raising significant funding to finance its cutting-edge, yet capital-intensive, preclinical research.
Market segment debts - Dna
Metagenomi is a genetic engineering company that uses its tools to develop potential therapeutics. This is one of the most advanced fields in biotechnology. The chart shows the financial norms for the biotech sector, where companies raise vast amounts of capital to finance their fundamental research and turn it into future drugs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Metagenomi Inc.
Metagenomi is a leading gene editing company developing a new generation of therapeutic tools. This is cutting-edge science, but it's extremely capital-intensive. This chart shows how much the company relies on debt to finance its breakthrough, yet highly risky, research. It's a key indicator of financial vulnerability.
Market segment debt to market segment book capitalization - Dna
The development of genome editing technologies like Metagenomi's is at the cutting edge of science and has the potential to transform medicine. This chart shows how the biotech sector is funding its most ambitious projects. It allows us to assess how capital-intensive this technology is and how the company's financial model compares to other CRISPR pioneers, such as Intellia and Editas.
Debt to book value of all companies in the market
Metagenomi is a company focused on genetic engineering and genome editing. This is at the absolute cutting edge of science, requiring massive investment in the research phase. The chart shows how this pioneering company's debt obligations compare to more traditional and profitable market sectors.
P/E of the company, segment and market as a whole
P/E - Metagenomi Inc.
This valuation for Metagenomi, Inc., a company developing a new generation of gene editing systems, reflects faith in its technology. Its value is determined not by current profits, but by the potential of its tools to surpass existing technologies, such as CRISPR, and revolutionize medicine.
P/E of the market segment - Dna
This indicator represents the average valuation for the biotech sector in which Metagenomi operates. It reflects the overall level of hope and expectation in the field of genetic engineering. The chart serves as a barometer of investor confidence in the future of genome editing technologies.
P/E of the market as a whole
Metagenomi is a genetic engineering company. It uses its platform to discover and develop new gene editing systems that could be more precise and versatile than CRISPR-Cas9. This chart shows interest in breakthrough technologies and helps understand whether the market believes Metagenomi can create the next generation of gene therapy tools.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Metagenomi Inc.
Metagenomi is a biotech company developing a new generation of gene editing tools based on its extensive microbiome database. The company's future depends on the success of its platform and therapeutic programs. This graph reflects investors' high expectations for its ability to create more versatile and precise tools than CRISPR-Cas9.
%20P%2FE%20Metagenomi%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Metagenomi-Inc.&v=1772681569010 "Chart of the company's future (projected) P/E Metagenomi Inc.")
Future (projected) P/E of the market segment - Dna
Metagenomi is a genetic engineering company developing a new generation of genome editing tools beyond CRISPR/Cas9. It's at the cutting edge of science. This chart reflects expectations for the biotech sector, helping to assess how highly the market values this potential technological breakthrough.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772681569012 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Metagenomi is a gene-editing company developing a new generation of tools (beyond CRISPR) for gene therapy. Their work is at the cutting edge of science. This graph of overall expectations shows how willing investors are to invest in fundamental research. Market optimism and faith in genetic medicine are essential for funding such breakthrough platforms.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772681569017 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Metagenomi Inc.
Metagenomi is a gene editing company developing therapeutics based on CRISPR systems. This chart reflects the financial health of the biotech innovator. Profitability is a long-term goal, and current performance reflects investments in the creation and development of a vast library of genome editing tools.
Profit of companies in the market segment - Dna
111, Inc. is one of the leading digital pharmacies and healthcare platforms in China. Its profitability depends on drug sales volume and competition in the healthtech sector. This chart illustrates how the digitalization of healthcare in China is creating a huge market, but regulatory changes and price competition are ongoing challenges to profitability.
Overall market profit
Metagenomi is a gene editing company that develops therapeutics based on its extensive database of CRISPR enzymes. The company is at the forefront of the biotech revolution. Its success depends on scientific breakthroughs that could lead to new treatments for genetic diseases.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Metagenomi Inc.
Metagenomi is a genetic engineering company developing a new generation of metagenomics-based genome editing tools. Its revenue forecast is long-term and depends on the success of its technology. This chart reflects analyst expectations regarding the future of gene therapy and the potential of the Metagenomi platform.
%20profit%20of%20the%20company%20Metagenomi%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Metagenomi-Inc.&v=1772681569039 "Graph of future (projected) profit of the company Metagenomi Inc.")
Future (predicted) profit of companies in the market segment - Dna
Metagenomi is a gene editing company developing a comprehensive suite of gene therapy tools based on CRISPR and other systems. The company's platform enables the creation of drugs for a wide range of diseases. This chart shows profitability forecasts for the biotech sector, reflecting the enormous potential and competition in the rapidly evolving field of genome editing.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772681569044 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Metagenomi is a company developing the next generation of gene editing systems. This is a fundamental technology for biomedicine. The overall economic forecast reflected in this chart influences the flow of venture capital and R&D budgets of large pharmaceutical companies, which are potential partners and clients for such platforms.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772681569047 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Metagenomi Inc.
Metagenomi is a genetic engineering company that uses its proprietary microbial database to discover and develop new gene editing systems beyond CRISPR/Cas9. The company has no commercial revenue. Its chart reflects the high valuation of its technology platform, which has the potential to significantly expand the toolkit for gene therapy.
P/S market segment - Dna
Metagenomi, Inc. is a gene medicine company that uses its cutting-edge platform to discover and develop new genome editing tools for therapeutic purposes. This chart shows the average valuation in the sector, providing insight into the market's perception of the revenue potential of Metagenomi's breakthrough scientific platform.
P/S of the market as a whole
Metagenomi is a genetic engineering company developing a new generation of genome editing tools based on metagenomics data. This chart, showing average valuations, clearly demonstrates the gap between the valuations of companies with current sales and the valuations of scientific platforms with enormous long-term potential.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Metagenomi Inc.
Metagenomi is a genetic engineering company developing a genome editing platform using a vast database of enzymes found in nature. This chart reflects investors' confidence in the future commercial success of its technology. The valuation is based on expected revenue from partnerships and licensing of this cutting-edge platform.
%20P%2FS%20Metagenomi%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Metagenomi-Inc.&v=1772681569090 "The graph of the company's future (projected) P/S Metagenomi Inc.")
Future (projected) P/S of the market segment - Dna
Metagenomi is a genetic engineering company developing a new generation of CRISPR-based genome editing systems. Its goal is to create more precise and effective gene therapy tools. The chart shows the premium investors are willing to pay for Metagenomi's future earnings, reflecting the potential of its cutting-edge technologies.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772681569097 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
This chart reflects the belief in the revolutionary potential of CRISPR gene editing technology. Metagenomi, with its vast database of gene-editing enzymes, is striving to create more precise and versatile gene therapy tools. Their scientific platform supports investors' long-term optimism in the technology's ability to treat genetic diseases.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772681569113 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Metagenomi Inc.
Metagenomi is a preclinical company developing a new generation of gene editing systems. Currently, the company has no commercial revenue, and its cash flow curve reflects funding milestones for its cutting-edge research and development, not sales. Future revenue will depend on the successful licensing of its technologies.
Sales of companies in the market segment - Dna
Metagenomi is a genetic engineering company developing a new generation of genome editing tools based on technologies other than CRISPR. This chart shows the total revenue in the DNA technology sector. It illustrates the rapid progress in gene therapy and the race to create more precise and safe tools for correcting genetic errors.
Overall market sales
Metagenomi is a gene editing company that uses algorithms and AI to discover and develop new genome editing systems from natural sources. Its goal is to create more effective and safe therapeutics. Its success depends on its technology platform. This graph of the overall economic climate influences the funding of breakthrough biotech platforms.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Metagenomi Inc.
Metagenomi is a gene editing company. It is developing a new generation of gene therapy tools using its proprietary enzyme discovery platform. The company's future depends on the success of its R&D. The chart shows analysts' speculative forecasts, betting on a breakthrough in genetic engineering.
%20sales%20of%20the%20company%20Metagenomi%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Metagenomi-Inc.&v=1772681569195 "Schedule of future (projected) sales of the company Metagenomi Inc.")
Future (projected) sales of companies in the market segment - Dna
Metagenomi is a gene editing company that uses a vast database of microbial genomes to discover new enzymes for CRISPR and other systems. Its goal is to create a universal toolkit for gene therapy. This chart shows projected sales for the entire DNA technology segment, reflecting expected growth in the gene editing market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772681569208 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Metagenomi is a gene editing company developing a new generation of therapeutics. The company is in its early stages, and its value is determined by the potential of its scientific platform. This overall economic performance impacts investor risk appetite, which determines the funding of such breakthrough, yet very long-term, technologies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772681569239 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Metagenomi Inc.
Metagenomi is a gene editing company developing therapeutics based on CRISPR technology. This metric reflects the financial side of cutting-edge science, demonstrating the level of investment in research and development required to commercialize its powerful gene editing platform.
Market segment marginality - Dna
Metagenomi is a gene editing company developing therapeutics using its extensive enzyme database. Profitability is a long-term goal, dependent on the success of its platform. This metric reflects its operational structure and level of investment in this cutting-edge field of biotechnology.
Market marginality as a whole
Metagenomi is a gene editing company developing therapeutics using its extensive CRISPR enzyme database. Their goal is to treat genetic diseases. Being in the early stages, their valuation depends on scientific breakthroughs. This overall profitability curve impacts them through the availability of capital for long-term biotech projects.
Employees in the company, segment and market as a whole
Number of employees in the company Metagenomi Inc.
Metagenomi is a gene editing company that uses naturally discovered enzymes to create new therapeutics. Its core asset is scientific discovery. This chart shows the growth of its team of scientists and bioinformaticians, who are expanding their arsenal of gene therapy tools and developing their development portfolio.
Share of the company's employees Metagenomi Inc. within the market segment - Dna
Metagenomi is a genetic engineering company that uses a vast database of microbial genomes to discover new gene-editing systems. This graph shows the concentration of elite scientists in this cutting-edge field. The Metagenomi team is expanding the gene therapy toolkit.
Number of employees in the market segment - Dna
Metagenomi, Inc. is a biotechnology company developing a new generation of gene editing systems for therapeutic purposes. This chart shows overall employment in the DNA analysis sector. It illustrates the cutting edge of science, where Metagenomi is using its discoveries to create more precise and versatile genetic engineering tools.
Number of employees in the market as a whole
Metagenomi is a genetic engineering company that uses cutting-edge gene editing technologies (including CRISPR) to develop potential therapeutics. It's at the cutting edge of science. This chart illustrates the job market, where such breakthrough companies are creating demand for geneticists, molecular biologists, and bioinformatics specialists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Metagenomi Inc. (MGX)
Metagenomi, Inc. is a genetic engineering company developing a new generation of genome editing tools. This chart reflects market expectations for this breakthrough technology. The astronomical market capitalization per employee suggests that investors believe in the platform's potential to transform medicine, and this belief drives the company's value, not the team's current performance.
%20of%20the%20company%20Metagenomi%20Inc.%20(MGX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Metagenomi-Inc.-MGX&v=1772681569380 "Chart of market capitalization per employee (in thousands of dollars) of the company Metagenomi Inc. (MGX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Metagenomi is a genetic engineering company using a comprehensive set of genome editing tools. This is one of the most advanced areas of biotechnology. This metric reflects the significant premium the market places on their technology platform. A high metric reflects investors' belief that their technology will transform medicine.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772681569391 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Metagenomi, Inc. is a company developing a new generation of gene editing systems. It's a "deep tech" in biotech. Its high market capitalization per employee reflects not current revenue, but the enormous potential of its technology to create new treatments for genetic diseases, which could outperform existing approaches such as CRISPR.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772681569400 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Metagenomi Inc. (MGX)
Metagenomi (MGX) is a preclinical-stage biotech R&D company developing next-generation gene-editing systems (CRISPR). This is cutting-edge science. This chart reflects their early stage: it shows the net loss (investment in R&D) per scientist working on this platform.
%20Chart%20Metagenomi%20Inc.%20(MGX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Metagenomi-Inc.-MGX&v=1772681569434 "Company Profit Per Employee (in thousands of dollars) Chart Metagenomi Inc. (MGX)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Metagenomi is a company at the forefront of gene editing. This metric isn't applicable at the preclinical stage. This chart represents a benchmark for mature biotech companies. Metagenomi's goal is to create and license gene therapy tools that will deliver colossal returns, far exceeding any standard.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772681569459 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Metagenomi (MGX) is a gene editing company developing a new generation of tools (beyond CRISPR) for gene therapy. This is cutting-edge science. This chart shows the economics of their R&D. The company is in its early stages, and each scientist employed is an investment leading to negative returns.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772681569474 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Metagenomi Inc. (MGX)
For Metagenomi, a company developing a new generation of gene editing systems, this graph reflects the advanced research stage. Revenue per employee, if any, comes from partnerships, and commercial success depends on a future therapeutic revolution.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Metagenomi-Inc.-MGX&v=1772681569499 "Sales chart per company employee Metagenomi Inc. (MGX)")
Sales per employee in the market segment - Dna
Metagenomi is an early-stage company developing a new generation of gene editing systems for therapeutic purposes. It has deep R&D capabilities. This metric reflects the average revenue per employee for the segment. It demonstrates how productive their team of scientists is in this cutting-edge field compared to other gene therapy companies.
Sales per employee for the market as a whole
Metagenomi (MGX) is a preclinical company developing a new generation of gene editing systems (CRISPR). It's a pure R&D company. This metric is an indicator of the future for MGX. Zero values currently reflect the development stage. A rising metric would indicate that their technology is being licensed or that a major partnership is being formed.
Short shares by company, segment and market as a whole
Shares shorted by company Metagenomi Inc. (MGX)
Metagenomi is an early-stage biotech company developing a new generation of gene-editing tools. Its IPO comes at a challenging time for biotech. This chart reflects investor bets that its technology, while promising, is too early and speculative and will face significant scientific and competitive hurdles.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Metagenomi-Inc.-MGX&v=1772681569627 "Short Shares Chart for the Company Metagenomi Inc. (MGX)")
Shares shorted by market segment - Dna
Metagenomi (MGX) is a gene editing company with a large portfolio of new genomic engineering tools. This chart shows the cumulative short interest in the speculative gene therapy sector. It reflects the immense investor skepticism regarding the technical challenges, patent wars, and high development costs in this field.
Shares shorted by the overall market
Metagenomi (MGX) is a biotech company focused on gene editing (CRISPR). It's one of the most advanced and speculative technologies. When this market fear indicator rises, investors aren't willing to wait 10 years. They're selling off "scientific projects" without profits, like MGX, en masse to cash out.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Metagenomi Inc. (MGX)
This chart for Metagenomi is an indicator of the hype surrounding the "next generation" of gene editing. The company is developing new, more precise tools (not CRISPR-Cas9) for therapeutics. As with the entire sector, positive preclinical data or partnerships with Big Pharma trigger "overheating" (above 70). Any concerns about safety or efficacy (off-target effects) lead to panic (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Metagenomi-Inc.-MGX&v=1772681569735 "RSI 14 indicator chart for the company's stock Metagenomi Inc. (MGX)")
RSI 14 Market Segment - Dna
Metagenomi (MGX) is "GMO" 2.0 (like Cibus). They're a *biotech* that uses *gene editing* to *create* gene therapy. The "Dna" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of the *entire* segment. It's vital to understand: is MGX's growth due to their R&D, or is *the entire* biotech sector "overheated"?
RSI 14 for the overall market
Metagenomi (MGX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MGX (Metagenomi Inc.)
Metagenomi is a biotech company at the forefront of gene editing. It uses AI to mine thousands of new enzymes (beyond CRISPR/Cas9) for gene therapy. This chart shows the speculative average price target from analysts, based on their belief in this powerful R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MGX-Metagenomi-Inc.&v=1772681569821 "A chart showing analyst consensus forecasts for the expected stock price. MGX (Metagenomi Inc.)")
The difference between the consensus estimate and the actual stock price MGX (Metagenomi Inc.)
Metagenomi (MGX) is a biotech R&D company that uses AI to search nature for new gene-editing "scissors" (CRISPR). This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high potential analysts see in their genomic tool discovery platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MGX-Metagenomi-Inc.&v=1772681569940 "A chart showing the difference between the consensus forecast and the actual stock price. MGX (Metagenomi Inc.)")
Analyst consensus forecast for stock prices by market segment - Dna
Metagenomi (MGX) is a biotech company developing next-generation gene editing tools, aiming to create more precise and versatile "scissors" than CRISPR. This chart shows analysts' overall expectations for the DNA technology sector, reflecting their confidence in this cutting-edge R&D platform.
Analysts' consensus forecast for the overall market share price
Metagenomi is a biotech company specializing in genome editing. They use AI to discover new enzymes (beyond CRISPR) for gene therapy. This chart shows the overall risk appetite. For Metagenomi, working in one of the most advanced and risky areas of medicine, overall market optimism is critical for funding R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Metagenomi Inc.
Metagenomi is a biotech company working in the hot field of gene editing. Unlike the pioneers, they use AI and machine learning to discover and create thousands of new, patented genome editing enzymes. This chart is a clear indicator of faith in their platform. It reflects the market's appreciation of their arsenal of tools and their partnerships (Moderna, Ionis).
AKIMA Market Segment Index - Dna
Metagenomi, Inc. (MGX) is a gene editing company developing therapeutics using its CRISPR-based platform and other systems. It's at the cutting edge of science. The chart shows the average index for the segment. It helps investors weigh Metagenomi's enormous potential and high risks against average expectations in the gene editing sector.
The AKIM Index for the overall market
Metagenomi is a genetic medicine company using metagenomics to discover new gene editing systems (beyond CRISPR). This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop critical for funding this cutting-edge early-stage scientific platform.
